Krishna Institute of Medical Sciences Limited (IN:KIMS)
:KIMS
Top Page
Krishna Institute of Medical Sciences Limited
(KIMS)
Select Model
Select Model
Rating:65Neutral
Price Target:
₹673.00
▲(3.06% Upside)
Action:ReiteratedDate:10/14/25
Krishna Institute of Medical Sciences Limited demonstrates strong financial performance with significant revenue and profit growth. However, the stock's high valuation and bearish technical indicators suggest caution. The company's increased leverage and negative free cash flow are potential risks that need monitoring.
Positive Factors
Sustained revenue growth
Sustained revenue growth from 16.5B to 30.4B (2022–2025) reflects durable demand for multi‑specialty hospital services and successful expansion. This scale gain supports long-term margin leverage, higher throughput, and greater bargaining power with payers and suppliers.
Negative Factors
Rising leverage
Debt-to-equity of 1.20 represents materially higher leverage versus prior periods. While equity remains healthy, elevated debt increases interest and refinancing risk, reduces financial flexibility for growth or shocks, and can amplify earnings volatility if margins compress.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth
Sustained revenue growth from 16.5B to 30.4B (2022–2025) reflects durable demand for multi‑specialty hospital services and successful expansion. This scale gain supports long-term margin leverage, higher throughput, and greater bargaining power with payers and suppliers.
Read all positive factors
Krishna Institute of Medical Sciences Limited (KIMS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹250.57B
Dividend YieldN/A
Average Volume (3M)23.04K
Price to Earnings (P/E)114.0
Beta (1Y)0.73
Revenue Growth25.74%
EPS Growth1.41%
CountryIN
Employees5,013
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.30
Shares Outstanding400,138,950
10 Day Avg. Volume26,167
30 Day Avg. Volume23,042
Financial Highlights & Ratios
PEG Ratio2.68
Price to Book (P/B)11.57
Price to Sales (P/S)8.24
P/FCF Ratio-57.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹792.50Price Target Upside21.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)13.5
Revenue Forecast (FY)₹49.77B
Krishna Institute of Medical Sciences Limited Business Overview & Revenue Model
Company Description
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reprod...
How the Company Makes Money
KIMS primarily makes money by delivering hospital and clinical services to patients through its owned/operated hospitals. The core revenue streams typically include: (1) Inpatient services (IP): revenue from admissions, bed/room charges, nursing a...
Krishna Institute of Medical Sciences Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.70B | 30.04B | 24.74B | 21.68B | 16.51B | 13.12B |
| Gross Profit | 20.12B | 18.77B | 15.21B | 13.41B | 10.34B | 8.19B |
| EBITDA | 8.24B | 8.24B | 6.52B | 6.43B | 5.46B | 3.78B |
| Net Income | 3.36B | 3.85B | 3.10B | 3.36B | 3.33B | 2.01B |
Balance Sheet | ||||||
| Total Assets | 66.25B | 57.36B | 38.52B | 29.41B | 19.07B | 14.36B |
| Cash, Cash Equivalents and Short-Term Investments | 1.74B | 1.02B | 1.32B | 1.34B | 1.90B | 2.84B |
| Total Debt | 31.87B | 25.57B | 13.55B | 6.78B | 2.57B | 3.16B |
| Total Liabilities | 40.49B | 33.17B | 17.59B | 10.03B | 4.97B | 5.60B |
| Stockholders Equity | 22.70B | 21.38B | 18.28B | 16.70B | 13.87B | 8.64B |
Cash Flow | ||||||
| Free Cash Flow | -4.69B | -4.27B | -1.26B | -1.42B | 1.54B | 2.62B |
| Operating Cash Flow | 2.85B | 5.82B | 5.21B | 4.32B | 3.24B | 3.56B |
| Investing Cash Flow | -7.17B | -11.16B | -7.53B | -5.47B | -4.12B | -3.54B |
| Financing Cash Flow | 4.57B | 5.43B | 2.17B | 196.42M | 609.99M | 98.19M |
Krishna Institute of Medical Sciences Limited Technical Analysis
Negative
653.00
Price Trends
658.14
Negative
658.37
Negative
689.78
Negative
Market Momentum
-13.93
Positive
40.23
Neutral
21.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KIMS, the sentiment is Negative. The current price of 653 is below the 20-day moving average (MA) of 659.85, below the 50-day MA of 658.14, and below the 200-day MA of 689.78, indicating a bearish trend. The MACD of -13.93 indicates Positive momentum. The RSI at 40.23 is Neutral, neither overbought nor oversold. The STOCH value of 21.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KIMS.
Krishna Institute of Medical Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹344.42B | 75.82 | ― | 0.24% | 14.72% | 8.37% | |
67 Neutral | ₹80.41B | -247.47 | ― | ― | 17.58% | -38.20% | |
65 Neutral | ₹250.57B | 114.01 | ― | ― | 25.74% | 1.41% | |
65 Neutral | ₹277.85B | 83.79 | ― | 0.04% | 15.78% | 15.01% | |
62 Neutral | ₹347.24B | 151.95 | ― | 0.84% | -36.14% | -93.99% | |
61 Neutral | ₹610.08B | 86.12 | ― | 0.11% | 15.33% | 54.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:KIMS
Krishna Institute of Medical Sciences Limited
626.20
56.85
9.99%
IN:ASTERDM
Aster DM Healthcare Ltd.
670.20
197.49
41.78%
IN:FORTIS
Fortis Healthcare Ltd.
808.10
176.50
27.94%
IN:HCG
HealthCare Global Enterprises Ltd.
538.55
21.65
4.19%
IN:MEDANTA
Global Health Limited
1,033.70
-161.67
-13.52%
IN:NH
Narayana Hrudayalaya Ltd.
1,685.35
46.86
2.86%
Krishna Institute of Medical Sciences Limited Corporate Events
KIMS Closes Trading Window Ahead of FY26 Audited Results
Mar 26, 2026
Krishna Institute of Medical Sciences Limited has announced the closure of its trading window from 1 April 2026 until 48 hours after it declares its audited standalone and consolidated financial results for the quarter and year ending 31 March 202...
KIMS Publishes Postal Ballot Notice, Confirms E-Voting and Dispatch Compliance
Mar 17, 2026
Krishna Institute of Medical Sciences Limited has notified the stock exchanges that it has published a postal ballot notice in two newspapers, Financial Express in English and Navatelangana in Telugu, as required under Indian company law and SEBI ...
KIMS Board Clears Plan to Raise Up to ₹1,500 Crore via Equity Issuance
Mar 11, 2026
Krishna Institute of Medical Sciences Limited, a leading Indian hospital chain, has approved a significant capital-raising plan to support its growth and operational needs. The company’s board has cleared a proposal to issue equity shares, p...
KIMS Sets Post-Q3 FY26 Earnings Call to Outline Strategy and Outlook
Feb 2, 2026
Krishna Institute of Medical Sciences Limited has announced that its top management, including Founder and Managing Director Dr. Bhaskara Rao Bollineni, Executive Director and CEO Dr. Abhinay Bollineni, and Chief Financial Officer Mr. Sachin Salvi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.